In Depth 13 Mar 2024From LSD to healing minds: Where are we standing in psychedelic drug development? Delve into the growing sector of psychedelic drug development to find out where we are coming from, and where we are standing in the field. March 13, 2024 - 13 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 11 Mar 2024Biotech bankruptcies: what to expect in 2024 following a record year? 2023 broke the record for the highest number of biotech bankruptcies in a decade. Can biotechs mitigate the risk in 2024? March 11, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 7 Mar 2024Can AbbVie’s legacy live beyond its once best-selling drug Humira? The sales of AbbVie’s Humira, once a best-seller, have dropped. Now, with a new CEO announced, things are about to change for the company. March 7, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 6 Mar 2024The biggest private biotech investments in February 2024 The companies BioAge Labs, Latigo Biotherapeutics, and Neurona Therapeutics bagged the biggest private biotech investments in February 2024. March 6, 2024 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 4 Mar 2024ALS: how close are we to a cure? Let us take a look at how the hunt for amyotrophic lateral sclerosis (ALS) drugs has advanced over the past few years. March 4, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 28 Feb 2024Beyond fundraising: how do venture capitals build early-stage biotechs? Venture capitals can help build early-stage biotech startups and boost innovation in the life science industry. February 28, 2024 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 27 Feb 2024Can the Novo Holdings-Catalent deal set a new standard for Pharma M&A? Explore the strategic implications of Novo Nordisk’s $16.5B Catalent acquisition on drug supply and market competition. February 27, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 26 Feb 2024New non-opioid pain medication: how is the biotech industry fighting pain after the opioid crisis? Find out how biotechs are fighting pain with new non-opioid pain medication, as they look to overcome the ongoing opioid crisis. February 26, 2024 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 22 Feb 2024TIL therapies: the impact on cancer research The approval of the first-ever TIL therapy has made it possible to treat hundreds of thousands of people affected by skin cancer in the US. February 22, 2024 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 21 Feb 2024Cytokine release syndrome: how pharma is tackling a 21st century disease Explore the frontier of biotech’s battle against cytokine release syndrome (CRS), from historical setbacks to cutting-edge solutions. February 21, 2024 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 15 Feb 2024Turning the tide: recent advancements in childhood cancer research As we observe International Childhood Cancer Day today, let us take a look at some of the recent advancements in childhood cancer research. February 15, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 15 Feb 2024Biogen: how is the biotech giant pivoting from a failed Alzheimer’s drug? Learn more about Biogen’s strategic realignment from Aduhelm’s controversy to Leqembi’s promise in Alzheimer’s treatment. February 15, 2024 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email